9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2021
The DOI matches its Crossref record; 90 of the 94 references it cites were found in a registry or an index.
Abstract
The American Diabetes Association (ADA) “Standards of Medical Care in Diabetes” includes the ADA's current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, a multidisciplinary expert committee (https://doi.org/10.2337/dc21-SPPC), are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA's clinical practice recommendations, please refer to the Standards of Care Introduction (https://doi.org/10.2337/dc21-SINT). Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org/SOC.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“the latest American Diabetes Association (ADA) [62], Italian Society of Diabetology (SID) [63] and KDIGO guidelines [64] differentiate the pharmacological approach to T2DM not just based on the target glycaemic values but also taking into account the indicators of high-risk or established atherosclerotic cardiovascular disease, CKD and heart failure.”
From GLP-1 receptor agonists and renal outcomes in patients with diabetes mellitus type 2 and diabetic kidney disease: state of the art (2022) · cites this paper as [62]
Citations
Cites
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes
(2005) · New England Journal of Medicine · doi:10.1056/nejmoa052187 · Cited by 5,138
Davies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetes Care · doi:10.2337/dci18-0033 · Cited by 3,518
Riddle (2003) · doi:10.2337/diacare.26.11.3080 · Cited by 1,479
Buse, J. B., Wexler, D. J., Tsapas, A., Rossing, P., Mingrone, G., Mathieu, C., D’Alessio, D. A., & Davies, M. J. (2020) · Diabetes Care · doi:10.2337/dci19-0066 · Cited by 1,192
Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus
The Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.287.19.2563 · Cited by 941
Maruthur, N. M., Tseng, E., Hutfless, S., Wilson, L. M., Suarez-Cuervo, C., Berger, Z., Chu, Y., Iyoha, E., Segal, J. B., & Bolen, S. (2016) · Annals of Internal Medicine · doi:10.7326/m15-2650 · Cited by 682
Threshold-based insulin-pump interruption for reduction of hypoglycemia
Bergenstal, R. M., Klonoff, D. C., Garg, S. K., Bode, B. W., Meredith, M., Slover, R. H., Ahmann, A. J., Welsh, J. B., Lee, S. W., & Kaufman, F. R. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1303576 · Cited by 652
Safety of a hybrid closed-loop insulin delivery system in patients with type 1 diabetes
Bergenstal, R. M., Garg, S., Weinzimer, S. A., Buckingham, B. A., Bode, B. W., Tamborlane, W. V., & Kaufman, F. R. (2016) · JAMA · doi:10.1001/jama.2016.11708 · Cited by 644 · cited 1×
“temshasbeensupported in the literature in adolescents and adults with type 1 diabetes (16,17), and recent evidence suggests that a closed-loop system is superior to sensor-augmented pump therapy for glycemic control and reduction of hypoglycemia over 3 months of comparison in children and adults with type 1 diabetes (…”
BackgroundHermansen, K., Davies, M., Derezinski, T., Martinez Ravn, G., Clauson, P., Home, P., & on behalf of the Levemir Treat-to-Target Study Group (2006) · Diabetes Care · doi:10.2337/dc05-1365 · Cited by 627
Research works printed but not linked: 3
- Peters, 2013, American Diabetes Association/JDRF Type 1 Diabetes Sourcebook
- Chiang, 2014, Type 1 diabetes through the life span: a position statement of the American Diabetes Association
- Lipska, 2018, Association of initiation of basal insulin analogs vs neutral protamine hagedorn insulin with hypoglycemia-related emergency department visits or hospital admissions and with glycemic control in patients with type 2 diabetes, 53
Cited by
Items 501–600 of 975
Abusnana, S., Alawadi, F., Aly, H., Bashier, A. M., Dhanwal, D. K., Halasa, T., Jallo, M. K. I., Medina, J., & Singhal, S. (2022) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2022.110183 · Cited by 8
Rotkvić, P. G., Ćelap, I., Lang, V. B., Jug, J., Snagic, A., Šipoš, I. H., & Berković, M. C. (2023) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2023.108541 · Cited by 8
Guo, L., Wang, J., Li, L., Yuan, L., Chen, S., Wang, H., Li, T., Qi, L., & Hong, Y. (2023) · BMC Medicine · doi:10.1186/s12916-023-02906-7 · Cited by 9
Rotkvić, P. G., Rotkvić, L., Đuzel, A., & Berković, M. C. (2024) · World Journal of Cardiology · doi:10.4330/wjc.v16.i8.448 · Cited by 8
Anjana, R. M., Siddiqui, M. K., Jebarani, S., Vignesh, M. A., Raj, N. K., Ranjit Unnikrishnan, I., Pradeepa, R., Panikar, V., Kesavadev, J., Saboo, B., et al. (2021) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2021.0277 · Cited by 7
“Author Disclosure Statement: No competing financial interests exist.”
Papachristou, S., Popovic, D. S., & Παπάνας, Ν. (2021) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3503 · Cited by 7
Ali, A. M., Cobran, E. K., & Young, H. N. (2022) · Pharmacy · doi:10.3390/pharmacy10040079 · Cited by 10
Sulfonylureas and Meglitinides
and, J. T., & Boyle, J. (2022) · Wiley eBooks · doi:10.1002/9781119785033.ch3 · Cited by 9
Meyer, J., Dreischmeier, E., Lehmann, M., & Phelan, J. (2022) · Annals of Pharmacotherapy · doi:10.1177/10600280221107381 · Cited by 6
Mattioli, I., Bettiol, A., Crescioli, G., Bonaiuti, R., Mannaioni, G., Vannacci, A., & Lombardi, N. (2023) · Healthcare · doi:10.3390/healthcare11020238 · Cited by 12
A drug mix and dose decision algorithm for individualized type 2 diabetes management
Nambiar, M., Bee, Y. M., Chan, Y. E., Mien, I. H., Guretno, F., Carmody, D., Lee, P. C., Chia, S. Y., Salim, N. N. M., & Krishnaswamy, P. (2024) · npj Digital Medicine · doi:10.1038/s41746-024-01230-5 · Cited by 12
“…the need to (1) expand the KDM guidelines for better management of patients with pre-visit HbA 1c well within and well above their glycemic target 2,3,35 ; and (2) offer multiple recommendations especially in cases where multifactorial considerations beyond the EMR such as capillary blood…”
InfluentialThe role of CRISPR-Cas9 and CRISPR interference technologies in the treatment of autoimmune diseases
Khademi, Z., Mottaghi-Dastjerdi, N., Morad, H., & Sahebkar, A. (2025) · Autoimmunity Reviews · doi:10.1016/j.autrev.2025.103816 · Cited by 6
Khan, S., Khawar, M., Khan, A., Ashraf, M. A., Iqba, J., Waqas, M. S., & Chaudhary, M. (2025) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-025-01795-2 · Cited by 6
“However, understanding demographic and regional trends in T2DM and AMI-related mortality remains crucial to assessing the evolving burden of these conditions.”
Gu, S., Hu, X., Zhen, X., Shi, L., Shao, H., Sun, X., Gu, Y., Huang, M., & Dong, H. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11185435 · Cited by 10
Gu, S., Hu, X., Shi, L., Zhen, X., Sun, X., Huang, M., Gu, Y., & Dong, H. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11237094 · Cited by 10
Lee, E. Y., Cho, J., Lee, W. J., Kim, N. H., Kim, J. H., & Lee, B. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.110884 · Cited by 7
Krishnan, K., Raman, S., Moses, C. R. A., Rajesh, R. P., Gupta, A., Mudaliar, V., & Vimal, J. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.111034 · Cited by 6
Wang, X., Ma, H., Li, X., Liang, Z., Fonseca, V. A., & Qi, L. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15443 · Cited by 6
Molteni, L., Marelli, G., Castagna, G., Brambilla, L., Acerbis, M., Alberghina, F., Carpani, A., Chiavenna, E., Ferlini, M. G., Impellizzeri, C., et al. (2024) · Endocrine Metabolic & Immune Disorders - Drug Targets · doi:10.2174/0118715303294909240221102552 · Cited by 10
“World Health Organization’s list of essential drugs and is recommended as a first-line therapy by all national and international guidelines [4-7].”
BackgroundMohamed, A. A., Al-Saffar, A., Mohamed, A. A., Khamis, M. H., Khalaf, A. A., Alaradi, H., Abuhamaid, A. I., Sanad, A. H., Abbas, H. L., Abdulla, A. M., et al. (2024) · Cureus · doi:10.7759/cureus.71739 · Cited by 8
PIONEER REAL Italy: Real-World Usage of Once-Daily Oral Semaglutide in Adults with Type 2 Diabetes
Manti, R., Cosmo, S. D., Desenzani, P., Ferrara, L., Girelli, A., Memoli, G., Bisio, A., Braae, U. C., Deinega, A., Berra, C., et al. (2025) · Diabetes Therapy · doi:10.1007/s13300-025-01719-6 · Cited by 9
“…statement also suggests that the addition of a new glucose-lowering agent to metformin should be individualized based on patient preferences and clinical characteristics such as established atherosclerotic cardiovascular disease (ASCVD), heart failure (HF), or chronic kidney disease (CKD) [4, 5].”
2021 Consensus Pathway of the Taiwan Society of Cardiology on Novel Therapy for Type 2 Diabetes
Chiang, C., Ueng, K., Chao, T., Lin, T., Wu, Y., Wang, K.-L., Sung, S., Yeh, H., Li, Y., Liu, P., et al. (2021) · JACC Asia · doi:10.1016/j.jacasi.2021.08.003 · Cited by 7
Silva‐Cardoso, J., Fonseca, C., Franco, F., Morais, J., Ferreira, J., & Brito, D. A. (2021) · Revista Portuguesa de Cardiologia · doi:10.1016/j.repc.2021.07.009 · Cited by 16
“62 In summary, we recommend that the traditional start low and go slow HFrEF therapy initiation aphorism 20 be changed to a start low and add fast strategy , which means starting the four foundational HF disease-modifying drug classes within a four to six week interval.”
Lasalvia, P., Gil-Rojas, Y., & Peña, Á. A. G. (2022) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1080/14737167.2022.2044310 · Cited by 6
Diabetes Management for Community Paramedics: Development and Implementation of a Novel Curriculum
Kasper, A. L., Myers, L. A., Carlson, P. N., Johnson, R. F., Schultz, J. L., Meyer, D., Liedl, C. P., Juntunen, M. B., & McCoy, R. G. (2022) · Diabetes Spectrum · doi:10.2337/ds21-0095 · Cited by 7
Terauchi, Y., Usami, M., & Inoue, T. (2022) · Advances in Therapy · doi:10.1007/s12325-022-02121-5 · Cited by 7
McCrimmon, R. J., PALMER, K. D., Alsaleh, A. J. O., Lew, E., & Puttanna, A. (2022) · Diabetes Therapy · doi:10.1007/s13300-022-01267-3 · Cited by 7
Kim, H., Bae, S., Yoon, H. Y., Yee, J., & Gwak, H. S. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac333 · Cited by 7
Viglino, F., Sellami, M., Broglio, F., Scuntero, P., Padovan, A. M., Maulini, C., Beccuti, G., Bragazzi, N. L., Barattucci, M., Kuvačić, G., et al. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12111865 · Cited by 6
Moskva, K. A., Kikhtyak, O. P., Lapovets, L., & Урбанович, А. М. (2022) · PROBLEMS OF ENDOCRINE PATHOLOGY · doi:10.21856/j-pep.2022.4.06 · Cited by 8
Effects of a New Group of Antidiabetic Drugs in Metabolic Diseases
Sanz‐Cánovas, J., Ricci, M., Cobos-Palacios, L., Sampalo, A. L., Hernández-Negrín, H., Vázquez-Márquez, M., Mancebo-Sevilla, J. J., Álvarez-Recio, E., Lopez-Carmona, M. D., Velasco, M. Á. P., et al. (2023) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2402036 · Cited by 6
“Patient comorbidities, risk of hypoglycemia, effects on body weight, side effects, costs, and patient preferences become important when choosing the best antidiabetic treatment for a patient [13].”
BackgroundTichler, A., Hertroijs, D. F. L., Ruwaard, D., Brouwers, M. C. G. J., Hiligsmann, M., de Jong, J. D., & Elissen, A. (2023) · Patient Preference and Adherence · doi:10.2147/ppa.s397647 · Cited by 4
Kan, M., Fu, H., Xu, Y., Yue, Z., Du, B., Chen, Q., Wang, X., Yu, S., & Zhang, Z. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15219 · Cited by 6
KD025 Is a Casein Kinase 2 Inhibitor That Protects Against Glucolipotoxicity in β-Cells
Devkota, R., Small, J. C., Carbone, K., Glass, M. A., Vetere, A., & Wagner, B. K. (2024) · Diabetes · doi:10.2337/db23-0506 · Cited by 7
Zhao, J., Hussain, S. A., & Maddu, N. (2024) · Acta Cirúrgica Brasileira · doi:10.1590/acb390124 · Cited by 7
Scutca, A.-C., Jugănaru, I., Nicoară, D.-M., Brad, G.-F., Bugi, M.-A., Asproniu, R., Cristun, L.-I., & Mărginean, O. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13092582 · Cited by 9
“DKA was considered if patients exhibited plasma glucose levels > 11 mmol/L, urine ketone levels categorized as moderate to high (+ to +++), and arterial pH values 7.30 upon admission [34].”
BackgroundMethodInfluentialLee, D., Oh, J. H., Jeon, H. J., & Oh, T. K. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01604-8 · Cited by 7
“Because of these beneficial findings attributed to SGLT2 inhibitors, the prescription of this class of drugs is now the first‑line choice to reduce cardiorenal adverse events in high‑risk patients with T2D [7].”
BackgroundMacIsaac, R. J. (2021) · Future Cardiology · doi:10.2217/fca-2020-0210 · Cited by 8
Rebello, C. J., Coulter, A. A., Reaume, A. G., Cong, W.-N., Cusimano, L. A., & Greenway, F. L. (2021) · Pharmaceuticals · doi:10.3390/ph14111196 · Cited by 6
Inaishi, J., Saisho, Y., Watanabe, Y., Tsuchiya, T., Sasaki, H., Masaoka, T., & Itoh, H. (2022) · BMC Endocrine Disorders · doi:10.1186/s12902-022-00932-9 · Cited by 6
Wang, W., Song, X. H., Lou, Y., Du, L., Zhu, D., & Zhou, Z. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14674 · Cited by 5
Vencio, S. A. C., Vianna, A. G. D., da Silva, M. A. C. F., & Précoma, D. B. (2022) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-021-00775-9 · Cited by 9
Kroopnick, J. M., & Davis, S. N. (2022) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2022.2089021 · Cited by 6
Yen, F., Wei, J. C., Chiu, L., Hsu, C., & Hwu, C. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.919881 · Cited by 6
Jiang, Y., Liu, R., Xuan, J., Lin, S., Zheng, Q., & Pang, J. (2023) · Clinical Drug Investigation · doi:10.1007/s40261-023-01255-w · Cited by 7
Colombijn, J. M. T., Idema, D. L., van Beem, S., Blokland, A. M., van der Braak, K., Handoko, M. L., Veld, L. F. H. I. ’., Kaul, T., Kolagasigil-Akdemir, N., Kusters, M. P. T., et al. (2023) · medRxiv · doi:10.1101/2023.07.18.23292848 · Cited by 6
Stewart, K. D., Matza, L. S., Patel, H., & Boye, K. S. (2023) · Journal of Patient-Reported Outcomes · doi:10.1186/s41687-023-00614-7 · Cited by 6
COPD and the burden of multimorbidity: navigating the complexity
Kallieri, M., Hillas, G., Bartziokas, Κ., Loukides, S., & Toumpanakis, D. (2025) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2025.2569126 · Cited by 8
“Glucagon-like peptide 1 (GLP-1) receptor agonists, sodium-glucose co-transporter-2 (SGLT-2) inhibitors and dipeptidyl peptidase 4 (DPP-4) inhibitors are widely used antihyperglycemic drugs with known cardiovascular benefits [143,144].”
Diabetes mellitus and hemodynamics in advanced heart failure
Heegaard, B., Deis, T., Rossing, K., Ersbøll, M. K., Kistorp, C., & Gustafsson, F. (2023) · International Journal of Cardiology · doi:10.1016/j.ijcard.2023.03.015 · Cited by 5
“An interesting development in the treatment of HF patients is the relatively new addition of sodium-glucose cotransporter 2 inhibitors (SGLT2-i), which were originally developed as an antidiabetic treatment [27].”
Metformin Extended-Release Oral Solution
Satterwhite, L. E. (2021) · Clinical Diabetes · doi:10.2337/cd21-0009 · Cited by 5
Snitker, S., Andersen, A., Berg, B., van Marle, S., & Sparre, T. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14349 · Cited by 5
Blonde, L., Fainberg, U., Kaltoft, M. S., Mosenzon, O., Ramesh, C. K., & Rea, R. R. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14464 · Cited by 5
Iizuka, K., Baxter, M., Watanabe, D., & Yabe, D. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14537 · Cited by 5
Insulin Resistance, Secretion and Clearance –Taming the Three Effector Encounter of Type 2 Diabetes
Bar‐Tana, J. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.741114 · Cited by 5
Intersection Between Diabetes and Heart Failure: Is SGLT2i the “One Stone for Two Birds” Approach?
Zhang, Q., Kang, Y., Tang, S., & Yu, C. (2021) · Current Cardiology Reports · doi:10.1007/s11886-021-01591-3 · Cited by 6
Practicable Measurement and Identification of Overbasalization
Cowart, K., & Carris, N. W. (2021) · Clinical Diabetes · doi:10.2337/cd21-0096 · Cited by 8
Cos, X., Gómez‐Huelgas, R., & Peralta, F. G. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01188-7 · Cited by 5
Wen, W., Huang, H., Lin, H.-C., Lo, W., Chen, S., & Lee, M. (2022) · Nutrients · doi:10.3390/nu14020320 · Cited by 5
Chronic Treatment with Metformin Has No Disrupting Effect on the Hepatic Circadian Clock in Mice
Hasan, N., Sugimoto, K., Yamada, K., Morishige, J., Ushijima, K., Fujimura, A., Nagata, N., & Ando, H. (2022) · Medicina · doi:10.3390/medicina58020293 · Cited by 5
Multimodal Treatment Approaches to Chronic Diseases
Maraş, G., & Sürme, Y. (2022) · Exploratory Research and Hypothesis in Medicine · doi:10.14218/erhm.2021.00079 · Cited by 5
Trends in Use of High-Cost Antihyperglycemic Drugs Among US Adults with Type 2 Diabetes
Le, P. N. B., Bui, T. C., Abramowitz, J., Herman, W. H., Misra‐Hebert, A. D., & Rothberg, M. B. (2022) · Journal of General Internal Medicine · doi:10.1007/s11606-022-07621-2 · Cited by 6
Colombijn, J. M. T., Idema, D. L., van der Braak, K., Spijker, R., Meijvis, S. C. A., Bots, M. L., Hooft, L., Verhaar, M. C., & Vernooij, R. W. M. (2022) · Systematic Reviews · doi:10.1186/s13643-022-02108-x · Cited by 5
Mohan, V., WANGNOO, S. K., Das, S., Dhediya, R., & Gaurav, K. (2022) · World Journal of Diabetes · doi:10.4239/wjd.v13.i12.1168 · Cited by 7
Brandon, R., Jiang, Y., Yeu, R. Q., Tweedie‐Cullen, R. Y., Smallman, K., Doherty, G., Macaskill-Smith, K. A., Doran, R. J., Clark, P., Moffitt, A., et al. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1091421 · Cited by 5
Wu, H., Lau, E. S. H., Yang, A., Fan, B., Ronald, C. W., Kong, A. P. S., Chow, E., So, W., Chan, J. C. N., & Luk, A. O. Y. (2023) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3615 · Cited by 6
Kolb, L. N., Othman, A., Rohrer, L., Krützfeldt, J., & von Eckardstein, A. (2023) · Biomolecules · doi:10.3390/biom13030497 · Cited by 5
Evaluation of calcium/magnesium ratio in patients with type 2 diabetes mellitus
Yücel, K., & Gürbüz, A. F. (2023) · Turkish Journal of Biochemistry · doi:10.1515/tjb-2023-0022 · Cited by 8
“We used standard international criteria to de fi ne “ glycemic control ” [34].”
MethodFan, M., Stephan, A., Emmert-Fees, K. M. F., Peters, A., & Laxy, M. (2023) · Diabetologia · doi:10.1007/s00125-023-05950-3 · Cited by 8
Lee, Y. J., Kang, N., Nam, J., Lee, E. G., Ryoo, J., Kwon, S. S., Kim, Y. H., & Kang, H. S. (2024) · PLoS ONE · doi:10.1371/journal.pone.0299484 · Cited by 5
Soluble T-cadherin secretion from endothelial cells is regulated via insulin/PI3K/Akt signalling
Okita, T., Kita, S., Fukuda, S., Kondo, Y., Sakaue, T., Iioka, M., Fukuoka, K., Kawada, K., Nagao, H., Obata, Y., et al. (2024) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2024.150403 · Cited by 7
Pharmacokinetics of metformin in collagen-induced arthritis rats
Chen, M., You, G., Xie, C., Yang, R., Hu, W., Zheng, Z., Liu, S., & Ye, L. (2021) · Biochemical Pharmacology · doi:10.1016/j.bcp.2021.114413 · Cited by 6
Best Achievements in Clinical Medicine in Diabetes and Dyslipidemia in 2020
Rhee, E., Kim, M. K., & Lee, W. (2021) · Endocrinology and Metabolism · doi:10.3803/enm.2021.106 · Cited by 6
Factors associated with work ability in adults with diabetes
McCarthy, M. M., Yan, J., & Dickson, V. V. (2021) · Applied Nursing Research · doi:10.1016/j.apnr.2021.151478 · Cited by 5
Prudencio, J. B., Cajudoy, P., & Waddell, D. (2021) · Pharmacy · doi:10.3390/pharmacy9040186 · Cited by 6
Wang, M. C., Dolan, B., Freed, B. H., Vega, L., Markoski, N., Wainright, A. E., Kane, B. J., Seegmiller, L. E., Harrington, K. A., Lewis, A., et al. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.785109 · Cited by 6
Malik, R. A., Elhadd, T. A., Alattar, A., Shaikh, A. A., Alrandi, M., Arora, R., Alsifri, S. N., Akil, Y. A., Magdy, A., Naqvi, M., et al. (2022) · Diabetes Therapy · doi:10.1007/s13300-022-01225-z · Cited by 6
Oral semaglutide - Rybelsus®, the first GLP-1 receptor agonist for oral use in clinical practice
Karásek, D. (2022) · Vnitřní lékařství · doi:10.36290/vnl.2022.018 · Cited by 8
Li, L., Tian, J., Wang, R., Adachi, J. D., Chen, B., Qu, H., & Li, G. (2022) · Rheumatology · doi:10.1093/rheumatology/keac254 · Cited by 6
The use of glucagon-like-peptide-1 receptor agonist in the cardiology practice
Martens, P., Mathieu, C., & Vanassche, T. (2022) · Acta cardiologica. Supplementum · doi:10.1080/00015385.2022.2076307 · Cited by 5
Shikdar, Y. A., Mosli, H. H., Shikdar, N. A., Alshanketi, R. M., Shikdar, N. A., Malebary, R. M., Aboznadah, W. M., & Shikdar, M. A. (2022) · Cureus · doi:10.7759/cureus.25312 · Cited by 5
Hung, W.-T., Chen, Y.-J., Cheng, C.-Y., Ovbiagele, B. I., Lee, M., & Hsu, C. (2022) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2022.109937 · Cited by 9
Hassanein, M. M., Akbar, M. A. J., Alshamiri, M. Q., Amir, A., Amod, A., Chudleigh, R. A., Elhadd, T. A., Heshmat, H., Jibani, M. M., & Saleh, Y. M. A. (2022) · Diabetes Therapy · doi:10.1007/s13300-022-01282-4 · Cited by 5
Sodium-Glucose Cotransporter 2 Inhibitor Use Among Individuals Age
Glover, S., Borrego, M. E., Ray, G. M., & Roberts, M. H. (2022) · ClinicoEconomics and Outcomes Research · doi:10.2147/ceor.s361886 · Cited by 5
Luthra, R., Bender, S. D., & Terada, D. (2022) · Clinical Therapeutics · doi:10.1016/j.clinthera.2022.07.009 · Cited by 5
Gasser, B. A., Calin, A.-E., Escher, G., Kurz, J., Emmenegger, A., Buerki, S., Schmidt‐Trucksäss, A., & Mohaupt, M. G. (2022) · Life · doi:10.3390/life12111736 · Cited by 5
Martínez-Solís, J., Calzada, F., Barbosa, E., & Gutiérrez-Meza, J. M. (2022) · Plants · doi:10.3390/plants11233224 · Cited by 6
Tamaki, J., Ogawa, S., Fujimori, K., Ishii, S., Nakatoh, S., Okimoto, N., Kamiya, K., & Iki, M. (2022) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-022-01372-0 · Cited by 5
Hadjkacem, F., Frikha, H., Boujelben, K., Chaari, C., Mnif, E., Masmoudi, A., Boudawara, T. S., Turki, H., & Abid, M. (2023) · Hospital Pharmacy · doi:10.1177/00185787231151861 · Cited by 5
Restrepo, P. A. T., Acosta-Reyes, J. L., Estupiñán-Bohorquez, A. F., Barrios-Mercado, M. A., Correa-González, N. F., Restrepo, A. T., Barengo, N. C., & Gabriel, R. (2023) · Current Diabetes Reports · doi:10.1007/s11892-023-01504-4 · Cited by 5
Cesta, C. E., Hernández–Díaz, S., Huybrechts, K. F., Bateman, B. T., Vine, S. M., Seely, E. W., & Patorno, E. (2023) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.5665 · Cited by 5
Gosmanov, A. R., Gemoets, D. E., Kaminsky, L. S., Kovesdy, C. P., & Gosmanova, E. O. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14414 · Cited by 5
Jang, H. N., Yang, Y., Oh, T. J., Koo, B. K., Lee, S. O., Park, K. S., Jang, H. C., & Jung, H. S. (2021) · Journal of Diabetes Investigation · doi:10.1111/jdi.13634 · Cited by 4
Balis, L. E., Houghtaling, B., & Buck, J. H. (2022) · Journal of Human Sciences and Extension · doi:10.54718/lakr5242 · Cited by 5
“DWD is coordinated through the National Extension Dining with Diabetes Working Group (NDWD), which provides leadership and coordination for unified program delivery and evaluation across states (Balis et al., 2022).”
BackgroundMethodChanging the diabetes treatment paradigm from glucose control to cardiorenal protection
Ekanayake, P. S., & Mudaliar, S. R. D. (2021) · International Journal of Microbiology Research · doi:10.4103/ijmr.ijmr_3114_21 · Cited by 5
Wang, H., Guan, L., Guan, H., Zhong, J., & Zhong, J. (2025) · Food Science & Nutrition · doi:10.1002/fsn3.70699 · Cited by 4
“…successful in preventing the development of diabetic complications, combined therapy has been recommended for the treatment of T2DM in order to achieve better control of blood glucose and to prevent the development of diabetic complications (American Diabetes Association 2021; Zhao et al. 2024).”
Genetically modified helminths as pharmaceutical biofactories
Walther, D., Smout, M. J., Giacomin, P., Brindley, P. J., Mitreva, M., Moyle, M., & Loukas, A. C. (2025) · Advances in Parasitology/Advances in parasitology · doi:10.1016/bs.apar.2025.08.001 · Cited by 6
The Role of Insulin Resistance in Cardiorenal Metabolic Syndrome
Xiao, J., Song, W. L., Huang, Y., He, X., Weng, Y., & Yu, H. (2025) · Cardiology in Review · doi:10.1097/crd.0000000000001048 · Cited by 5
Xie, L., & Luo, S. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02947-7 · Cited by 5
“This may be because early interventions and standard acute management approaches for diabetes may mitigate the effects of GV during the initial phase [39].”
Sheils, N. E., Jarvis, M. S., Bangerter, L. R., Asch, D. A., & Clark, C. N. (2022) · Diabetes Spectrum · doi:10.2337/ds22-0042 · Cited by 7
Rural-Urban Disparities in the Uptake of New Diabetes Medications
Zhu, B., Dong, D., Luo, J., & Glied, S. (2024) · Diabetes Spectrum · doi:10.2337/ds23-0075 · Cited by 5
Metadata
- Authors
- American Diabetes Association
- Corresponding author
- American Diabetes Association
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2020-12-04
- Volume
- 44
- Issue
- Supplement_1
- Pages
- S111-S124
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W4254445254
- Cited by
- 972
- References
- 94
- Citations by year
- 2026: 29 · 2025: 55 · 2024: 86 · 2023: 148 · 2022: 334 · 2021: 318 · 2020: 1
- FWCI
- 30.63
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
- Keywords
- pharmacotherapy, diabetes management, antidiabetic drugs, treatment goals, quality of care, clinical guidelines
- MeSH terms
- Blood Glucose, Diabetes Mellitus, Endocrinology, Humans, Societies, Medical, Standard of Care
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.